- Previous Close
2.6900 - Open
2.7000 - Bid 2.6000 x 100
- Ask 2.6800 x 100
- Day's Range
2.5001 - 2.7400 - 52 Week Range
0.5800 - 4.0440 - Volume
239,552 - Avg. Volume
548,949 - Market Cap (intraday)
115.874M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date May 1, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
www.rapidmicrobio.comRecent News: RPID
View MorePerformance Overview: RPID
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPID
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPID
View MoreValuation Measures
Market Cap
115.87M
Enterprise Value
71.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.16
Price/Book (mrq)
1.54
Enterprise Value/Revenue
2.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-167.16%
Return on Assets (ttm)
-25.82%
Return on Equity (ttm)
-48.50%
Revenue (ttm)
28.05M
Net Income Avi to Common (ttm)
-46.89M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
51.22M
Total Debt/Equity (mrq)
8.19%
Levered Free Cash Flow (ttm)
-28.83M